Latest news with #CardinalHealth
Yahoo
4 days ago
- Business
- Yahoo
Cardinal Health, Inc. (CAH) CEO Is 'Terrific,' Says Jim Cramer
Cardinal Health, Inc. (NYSE:CAH) is one of the . Cardinal Health, Inc. (NYSE:CAH) is one of the biggest healthcare products and services providers in America. The shares are up by 36% year-to-date as they have benefited from strong earnings and other tailwinds. Cramer has discussed Cardinal Health, Inc. (NYSE:CAH) several times in 2025. He believes that the firm's specialty pharma business is a key differentiating factor and added that it could benefit if the Trump Administration decides to shake things up in the pharmaceutical supply chain. Here are his latest thoughts about Cardinal Health, Inc. (NYSE:CAH): 'Okay, you know I got a company, I mentioned it yesterday, Cardinal Health. These, it's not a middleman. Everyone thinks it's just a middleman. Jason Hollar's carving out a real place to make healthcare, let's say better, streamlined, and cheaper. I just think this guy's terrific, and I'm happy to have him on the show. He's not a villain.' Cramer discussed Cardinal Health, Inc. (NYSE:CAH) in detail in May. Here is what he said: 'These stocks. . .are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… A senior physician in a modern healthcare institution administering medication to a patient. Now, if you really want to own one, and I do like this one, Cardinal Health is the one to do it with because it provides a lot more value-added services than the others. Now, we've had Cardinal on several times, and I think they're doing some very innovative things. They are impressive, they're beyond middlemen.' While we acknowledge the potential of CAH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
A strong stock as of late has been Cardinal Health (CAH). Shares have been marching higher, with the stock up 7.9% over the past month. The stock hit a new 52-week high of $166.03 in the previous session. Cardinal has gained 39.9% since the start of the year compared to the -4.9% move for the Zacks Medical sector and the -0.9% return for the Zacks Medical - Dental Supplies industry. The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 1, 2025, Cardinal reported EPS of $2.35 versus consensus estimate of $2.15 while it missed the consensus revenue estimate by 0.27%. For the current fiscal year, Cardinal is expected to post earnings of $8.16 per share on $223.11 billion in revenues. This represents a 8.37% change in EPS on a -1.71% change in revenues. For the next fiscal year, the company is expected to earn $9.14 per share on $245.33 billion in revenues. This represents a year-over-year change of 12% and 9.96%, respectively. Cardinal may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself. On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style. Cardinal has a Value Score of B. The stock's Growth and Momentum Scores are D and A, respectively, giving the company a VGM Score of B. In terms of its value breakdown, the stock currently trades at 20.3X current fiscal year EPS estimates, which is a premium to the peer industry average of 17.2X. On a trailing cash flow basis, the stock currently trades at 15.7X versus its peer group's average of 15X. Additionally, the stock has a PEG ratio of 1.85. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective. We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Cardinal currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Cardinal fits the bill. Thus, it seems as though Cardinal shares could still be poised for more gains ahead. Shares of CAH have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is McKesson Corporation (MCK). MCK has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of A, and a Momentum Score of F. Earnings were strong last quarter. McKesson Corporation beat our consensus estimate by 3.16%, and for the current fiscal year, MCK is expected to post earnings of $37.23 per share on revenue of $405.8 billion. Shares of McKesson Corporation have gained 1.4% over the past month, and currently trade at a forward P/E of 19.58X and a P/CF of 18.76X. The Medical - Dental Supplies industry is in the top 12% of all the industries we have in our universe, so it looks like there are some nice tailwinds for CAH and MCK, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
6 days ago
- Business
- Yahoo
Cardinal Health (NYSE:CAH) Targets Double-Digit EPS Growth Amid IRA Tailwinds and Healthcare Sector Strength
Cardinal Health, Inc. (NYSE:CAH) is one of the 15 best stocks to invest in for an 18 year old. BofA Securities analyst Michael Cherny raised his price target for Cardinal Health, Inc. (NYSE:CAH) shares from $165 to $170 on June 10 while reiterating his Buy rating for the company's shares. The change was made ahead of Cardinal Health's June 12 investor day, where the company is expected to provide an updated financial outlook. Expectations for the event are especially high, Cherny said, given Cardinal Health's impressive performance over the past two years in addition to positive industry trends, including higher utilization and adjustments to the Inflation Reduction Act (IRA) which influence out-of-pocket costs. In addition to potentially announcing improvements to its Pharmaceutical and Specialty Solutions EBIT growth forecasts, analysts expect Cardinal Health, Inc. (NYSE:CAH) to lay out the foundation for attaining sustainable double-digit earnings per share growth. Moreover, the company plans on updating investors about its latest forays into specialized fields, such as and Specialty networks. Cardinal Health, Inc. (NYSE:CAH) is a multinational health care services company that provides tailored solutions for ambulatory surgery centers, pharmacies, hospitals, and healthcare systems. While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
6 days ago
- Business
- Yahoo
Cardinal Health (CAH) Affirms Long-Term Growth Raises Outlook
Cardinal Health, Inc. (NYSE:CAH) is . On June 12, the company raised its fiscal year 2025 diluted earnings per share guidance to between $8.15 and $8.20 from an initial guidance of between $8.05 and $8.15. The company also established a preliminary fiscal year 2026 guidance of between $9.10 and $9.30, affirming expected growth. A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens. In addition, Cardinal Health is targeting a long-term compound annual growth rate of between 12% and 14% for its non-GAAP diluted EPS between 2026 and 2028. It also targets 5% to 7% long-term profit growth in its Pharmaceutical and Specialty Solutions segment. The company also targets $50 million of profit growth under its Global Medical Products and Distribution. Cardinal Health will achieve $10 billion in adjusted free cash flow over the next three years. It has already increased its baseline share repurchase plans to $750 million from $500 million. The company also plans to invest over $150 million in its Nuclear and Precision Health Solutions to support theranostics and PER product pipeline development. Cardinal Health, Inc. (NYSE:CAH) is a healthcare company that operates in various sectors, including pharmaceutical distribution, medical product manufacturing and distribution, and performance and data solutions for healthcare facilities. It provides solutions to different healthcare providers, from hospitals and clinics to pharmacies and home care services. While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
TD Cowen Affirms Buy Rating on Cardinal Health
Cardinal Health (NYSE:CAH) is . On June 10, analysts at TD Cowen reiterated a Buy rating and maintained a price target of $162 on the stock. A close-up of a person's hand holding a bottle of pharmaceuticals. The analysts expect the company to increase its long-term pharmaceutical profit guidance from 5% to 7% from a previous guidance of 4% and 6%. Cardinal Health is also expected to introduce preliminary adjusted earnings per share guidance in the range of $9.15 to $9.45. TD Cowen analyst also expects Cardinal Health to provide insights on how other segment businesses will contribute 18% of adjusted operating income. The company has entered into a distribution agreement with Citious Oncology to support the launch of FDA-approved immunotherapy LYMPHIR. Cardinal Health (NYSE:CAH) is a global healthcare company that distributes pharmaceuticals and specialty products. It also manufactures and distributes medical and laboratory products. While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
